Renibus Therapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Renibus Therapeutics sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 1 currently recruiting 5 completed early-phase tilt top decile by trial count

Renibus Therapeutics: 9 sponsored US clinical trials, 1 recruiting.

Renibus Therapeutics sponsors 9 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 5 completed. 2 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Post-discharge Outcomes, with 1 trials.

Top-decile sponsor footprint

Renibus Therapeutics ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 3

A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosis

NCT07355062
ACTIVE NOT RECRUITING

Retrospective Observational Study of Patients Who Have Undergone Coronary Artery Bypass Graft (CABG) and/or Cardiac Valve Surgery

NCT07009340
ACTIVE NOT RECRUITING

An Evaluation of Patient Reported Outcomes and Clinical Outcomes

NCT06092970
COMPLETED Phase 3

Effect of RBT-1 on Reducing the Risk of Post-Operative Complications in Subjects Undergoing Cardiac Surgery

NCT06021457
COMPLETED Phase 2

Effect of RBT-1 on Preconditioning Response Biomarkers in Subjects Undergoing CABG and/or Cardiac Valve Surgery

NCT04564833
TERMINATED Phase 2

A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)

NCT04364763
COMPLETED Phase 1

A Study of RBT-1 in Healthy Volunteers and Subjects With Stage 3/4 Chronic Kidney Disease

NCT03893799
COMPLETED Phase 1

A Study of RBT-9 in Healthy Volunteers and Volunteers With Stage 3/4 Chronic Kidney Disease

NCT04072861
COMPLETED Phase 1

A Study of RBT-3 in Healthy Volunteers and Volunteers With Stage 3/4 Chronic Kidney Disease

NCT04072432

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 2
Phase 3 2

Therapeutic Areas

Post-discharge Outcomes 1
Post-Operative Complications in Cardiac Surgery 1
CKD 1
AKI 1
Metabolic Acidosis 1
Chronic Kidney Disease 1
Healthy Volunteers 1

What is open in the Renibus Therapeutics pipeline

1 recruiting of 9 indexed (11% open); 5 completed (56%).

Phase mix: 2 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Post-discharge Outcomes (1 trial), 6 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Renibus Therapeutics: open-pipeline peers nationwide

Peers matched on 9 registered trials and 11% open enrollment, not the therapeutic-area sidebar.

Renibus Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 01020304050 0%10%20%30%40%50% Total trials Recruiting share Renibus Therapeutics4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyADC Therapeutics S.A.Adrian VellaAIDS Malignancy ConsortiumAmylyx Pharmaceuticals
Renibus Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Renibus Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 11% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Renibus Therapeutics page

9 registered trials is a research-attention snapshot, not an endorsement of Renibus Therapeutics or any single study.

  • 1 of Renibus Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Post-discharge Outcomes is the condition Renibus Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Post-discharge Outcomes trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Renibus Therapeutics pipeline card: 9 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.